Related Experiment Video

Updated: Aug 27, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.7K

KMT5A Knockdown Suppresses Osteosarcoma Cell Proliferation and Metastasis Through Ꞵ-Catenin Signalling

Jiangdong An1, Jin Zhang2, Zhaoheng Wang1

  • 1Department of Orthopedics, Lanzhou University Second Hospital, Lanzhou, P.R. China. email@email.com.

Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|September 23, 2022
PubMed
Abstract

Insights

KMT5A knockdown inhibits osteosarcoma (OS) cell proliferation and metastasis. This occurs via the β-catenin signaling pathway, suggesting KMT5A as a potential therapeutic target for OS.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Osteosarcoma (OS) is a prevalent bone cancer in young individuals.
  • Understanding the molecular mechanisms driving OS progression is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role and cellular mechanisms of KMT5A in osteosarcoma.
  • To explore KMT5A's impact on OS cell proliferation, metastasis, and survival.

Main Methods:

  • KMT5A protein expression was analyzed in clinical osteosarcoma tissues.
  • KMT5A was knocked down using siRNAs in the human OS cell line MG63.
  • Cell proliferation, death, migration, and invasion assays were performed.

Main Results:

  • KMT5A expression is elevated in osteosarcoma tissues.
  • KMT5A knockdown reduced proliferation, increased cell death, and suppressed migration/invasion.
  • KMT5A knockdown decreased cyclinD1, Bcl2, MMP3, and vimentin, while increasing cleaved-caspase9.
  • KMT5A regulates β-catenin signaling, which is upregulated in OS.

Conclusions:

  • KMT5A knockdown inhibits osteosarcoma cell proliferation and metastasis.
  • The inhibitory effects are mediated through the β-catenin signaling pathway.
  • KMT5A represents a potential therapeutic target for osteosarcoma treatment.
Keywords:
KMT5Aosteosarcomacell proliferationmetastasisβ-catenin

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.3K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.2K

Related Concept Videos

Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.9K
Catenins01:23

Catenins

Catenins are characterized by multiple binding domains and dynamic structures that allow them to function as linker proteins in cell junction complexes. All catenins, except α-catenin, contain a characteristic protein sequence called the armadillo repeat and are therefore also called armadillo proteins.
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K